Malken Bayrakdarian
Directeur/Membre du Conseil chez NuChem Sciences, Inc.
Profil
Malken Bayrakdarian currently works as an Executive Director at NuChem Sciences, Inc.
Postes actifs de Malken Bayrakdarian
Sociétés | Poste | Début |
---|---|---|
NuChem Sciences, Inc.
NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
NuChem Sciences, Inc.
NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Health Technology |